Editas Medicine News Releases http://ir.editasmedicine.com/ Editas Medicine News Releases en Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-presents-pre-clinical-data-treatment-sickle-cell IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass. , June 15, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today Sat, 15 Jun 2019 11:30:00 -0400 Editas Medicine News Releases 9426 Editas Medicine Announces First Quarter 2019 Results and Update http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2019-results-and-update - Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587) for LCA10 on track for first patient dosing in second half of 2019 - - Initiated IND-enabling activities for potentially Tue, 07 May 2019 16:01:00 -0400 Editas Medicine News Releases 9356 Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-host-conference-call-discussing-first-quarter-3 CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, May 7, 2019 , at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of Tue, 30 Apr 2019 16:01:00 -0400 Editas Medicine News Releases 9351 Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10) http://ir.editasmedicine.com/news-releases/news-release-details/allergan-and-editas-medicine-announce-initial-data-natural DUBLIN, Ireland and CAMBRIDGE, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced initial data from the ongoing natural history study to evaluate patients Mon, 29 Apr 2019 09:19:00 -0400 Editas Medicine News Releases 9346 Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-and-bluerock-therapeutics-enter-strategic – Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers – CAMBRIDGE, Wed, 03 Apr 2019 07:00:00 -0400 Editas Medicine News Releases 9321 Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-fourth-quarter-and-full-year-2018 EDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019 Advancing potentially best-in-class engineered cell medicine for sickle cell disease and beta-thalassemia Appointed Cynthia Collins and David Scadden , M.D., to Board Thu, 28 Feb 2019 16:01:00 -0500 Editas Medicine News Releases 9266 Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day® http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-supports-global-movement-raise-awareness-rare CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates around the world to help elevate Thu, 28 Feb 2019 09:00:00 -0500 Editas Medicine News Releases 9261 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-host-conference-call-discussing-fourth-quarter-2 CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 28, 2019 , at 5:00 p.m. ET to discuss a corporate update and results for the fourth Thu, 21 Feb 2019 16:02:00 -0500 Editas Medicine News Releases 9251 Editas Medicine Names David Scadden, M.D., to Board of Directors http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-names-david-scadden-md-board-directors CAMBRIDGE, Mass. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden , M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the Wed, 06 Feb 2019 09:00:00 -0500 Editas Medicine News Releases 9166 Editas Medicine Announces Chief Executive Officer Transition http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-chief-executive-officer-transition Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced Tue, 22 Jan 2019 09:00:00 -0500 Editas Medicine News Releases 9131